<SEC-DOCUMENT>0001171843-18-005277.txt : 20180723
<SEC-HEADER>0001171843-18-005277.hdr.sgml : 20180723
<ACCEPTANCE-DATETIME>20180723071530
ACCESSION NUMBER:		0001171843-18-005277
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20180723
FILED AS OF DATE:		20180723
DATE AS OF CHANGE:		20180723

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RedHill Biopharma Ltd.
		CENTRAL INDEX KEY:			0001553846
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35773
		FILM NUMBER:		18963593

	BUSINESS ADDRESS:	
		STREET 1:		21 HA'ARBA'A STREET
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			64739
		BUSINESS PHONE:		972-3-541-3131

	MAIL ADDRESS:	
		STREET 1:		21 HA'ARBA'A STREET
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			64739
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_072318.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><FONT STYLE="font-size: 12pt"><B>UNITED STATES </B></FONT><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Washington, D.C.&nbsp;20549</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>FORM 6-K</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Report of Foreign Private Issuer</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Pursuant to Rule 13a-16 or 15d-16</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>of&nbsp;the Securities Exchange Act of 1934</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0">For the month of July 2018<BR>
Commission File No.:001-35773</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0"><B>REDHILL BIOPHARMA LTD.</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0">(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>21 Ha'arba'a Street, Tel Aviv, 64739, Israel</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0">(Address of principal executive offices)</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0">&nbsp;</P>

<P STYLE="margin: 0; font-size: 10pt; text-align: justify">Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.&nbsp;&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0"><FONT STYLE="font-weight: normal; font-style: normal; text-transform: none">Form
20-F [&nbsp;X ] &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F [&nbsp;&nbsp; ]</FONT></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0">&nbsp;</P>

<P STYLE="margin: 0; font-size: 10pt; text-align: justify">Indicate by check mark if the Registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): ____&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0">&nbsp;</P>

<P STYLE="margin: 0; font-size: 10pt; text-align: justify">Indicate by check mark if the Registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): ____&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0">Attached hereto and incorporated by reference herein is a press
release issued by the Registrant entitled:<BR>
<I>&quot;RedHill Biopharma Announces Uplisting to Nasdaq Global Market&rdquo;</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0"><I></I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin-right: 0; margin-left: 0">This Form 6-K is incorporated by reference into
the Company's Registration Statements on Form S-8 filed with the Securities and Exchange Commission on May 2, 2013 (Registration
No. 333-188286), on October 29, 2015 (Registration No. 333-207654) and on July 25, 2017 (Registration No. 333-219441) and its
Registration Statement on Form F-3 filed with the Securities and Exchange Commission on February 25, 2016 (Registration No. 333-
209702).<B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Signatures</B>&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0">&nbsp;</P>

<P STYLE="margin: 0; font-size: 10pt; text-align: justify">Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.&nbsp;</P>

<P STYLE="margin: 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%">
        <P STYLE="font-size: 10pt; text-align: left; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: left; margin: 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: left; margin: 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: left; margin: 0">Date: July 23, 2018</P></TD>
    <TD STYLE="width: 10%; font-size: 10pt; text-align: left; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="width: 50%">
        <P STYLE="font-size: 10pt; text-align: left; margin: 0">REDHILL BIOPHARMA LTD.<BR>
        (the &quot;Registrant&quot;)<BR>
        <BR>
        By: /s/ <I>Dror Ben-Asher</I><BR>
        &mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;<BR>
        Dror Ben-Asher</P>
        <P STYLE="font-size: 10pt; text-align: left; margin: 0">Chief Executive Officer</P></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: left; margin: 0 0 13pt">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"><html lang="en-US"><head><title>EdgarFiling</title><meta content="text/html; charset=windows-1252" ><meta name="GENERATOR" content="MSHTML 8.00.7601.18094" ></head><body bgcolor="#ffffff"><p style="text-align: right;"><strong>EXHIBIT 99.1</strong></p><p style="text-align: center;"><strong>RedHill Biopharma Announces Uplisting to Nasdaq Global Market</strong></p><p style="text-align: center;" ></p><p>
 <p align="justify">TEL-AVIV, Israel and RALEIGH, N.C., July  23, 2018  (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (&#8220;RedHill&#8221; or the &#8220;Company&#8221;), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal diseases, today announced that Nasdaq Stock Market LLC has approved the uplisting of the Company&#8217;s American Depositary Shares (&#8220;ADSs&#8221;) on the Nasdaq Global Market. The ADSs were previously traded on the Nasdaq Capital Market. The listing of the ADSs on the Nasdaq Global Market was effective as of July 20, 2018, following satisfaction of certain financial and liquidity requirements. The Company&#8217;s ADSs will continue to trade uninterrupted under the symbol "RDHL".<br ></p>  <p align="justify"><strong>About RedHill Biopharma Ltd.:&#160;&#160;&#160;&#160;&#160; <br > </strong>RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) is a specialty biopharmaceutical company, primarily focused on the development and commercialization of late clinical-stage, proprietary drugs for the treatment of gastrointestinal diseases. RedHill has rights to four commercial gastrointestinal products in the U.S.: <strong>Donnatal<sup>&#174;</sup></strong> <strong>-</strong> a prescription oral adjunctive drug used in the treatment of IBS and acute enterocolitis; <strong>Mytesi<sup>&#174;</sup></strong> - an anti-diarrheal indicated for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy; <strong>Esomeprazole Strontium </strong><strong>Delayed-Release Capsules 49.3 mg - </strong>a prescription proton pump inhibitor indicated for adults for the treatment of gastroesophageal reflux disease (GERD) and other gastrointestinal conditions, and <strong>EnteraGam<sup>&#174;</sup></strong> <strong>-</strong> a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools. RedHill&#8217;s key clinical-stage development programs include: (i) <strong>TALICIA<sup>&#174;</sup> (RHB</strong><strong>-105)</strong> for the treatment of <em>Helicobacter pylori</em> infection with an ongoing confirmatory Phase III study and positive results from a first Phase III study; (ii) <strong>RHB-104,</strong> with an ongoing first Phase III study for Crohn's disease; (iii) <strong>RHB-204, </strong>with a planned pivotal Phase III study for nontuberculous mycobacteria (NTM) infections; (iv) <strong>BEKINDA<sup>&#174;</sup></strong><strong> (RHB-102),</strong> with positive results from a Phase III study for acute gastroenteritis and gastritis and positive results from a Phase II study for IBS-D; (v) <strong>YELIVA<sup>&#174;</sup> (ABC294640),</strong> a first-in-class SK2 selective inhibitor, targeting multiple oncology, inflammatory and gastrointestinal indications, with an ongoing Phase IIa study for cholangiocarcinoma; (vi) <strong>RHB-106,</strong> an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd. and (vii) <strong>RHB-107 (formerly MESUPRON), </strong>a Phase II-stage first-in-class, serine protease inhibitor, targeting cancer and inflammatory gastrointestinal diseases.</p>  <p align="justify"><em>This press release contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;plans,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;projects,&#8221; &#8220;predicts,&#8221; &#8220;estimates,&#8221; &#8220;aims,&#8221; &#8220;believes,&#8221; &#8220;hopes,&#8221; &#8220;potential&#8221; or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company&#8217;s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company&#8217;s research, manufacturing, preclinical studies, clinical trials, and other therapeutic candidate development efforts; (ii) the Company&#8217;s ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; (iii) the extent and number of additional studies that the Company may be required to conduct and the Company&#8217;s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company&#8217;s therapeutic candidates; (v) the Company&#8217;s ability to successfully promote Donnatal<sup>&#174;</sup> and Esomeprazole Strontium Delayed-Release Capsules 49.3 mg</em> <em>and commercialize EnteraGam<sup>&#174;</sup>; (vi) the Company&#8217;s ability to establish and maintain corporate collaborations; (vii) the Company's ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company&#8217;s therapeutic candidates and the results obtained with its therapeutic candidates in research, preclinical studies or clinical trials; (ix) the implementation of the Company&#8217;s business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) estimates of the Company&#8217;s expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative drugs under the Company's Expanded Access Program; and (xiv) competition from other companies and technologies within the Company&#8217;s industry. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEC </em><em>on February 22, 2018. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise, unless required by law.</em>&#160;</p> </p><p>Company contact:<br >Adi Frish<br >Senior VP Business Development & Licensing <br >RedHill Biopharma<br >+972-54-6543-112<br >adi@redhillbio.com<br ><br >IR contact (U.S.): <br >Timothy McCarthy, CFA, MBA<br >Managing Director, Relationship Manager<br >LifeSci Advisors, LLC<br >+1-212-915-2564<br >tim@lifesciadvisors.com</p></body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
